Federal grants to Selsym Biotech, Inc.
Selsym Biotech, Inc. in Cary, North Carolina received $2.7 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Military Medical Research and Development, with $2.0 million. It had no new grant money in fiscal 2025.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$2.7 million
- Awards4
- Awarded in FY 2025$0
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $254,878 |
| FY 2022 | 2 | $487,975 |
| FY 2023 | 1 | $2.0 million |
| FY 2024 | 0 | $0 |
| FY 2025 | 0 | $0 |
Programs that fund Selsym Biotech, Inc.
| Program | Awards | Amount |
|---|---|---|
| Military Medical Research and Development | 1 | $2.0 million |
| Cardiovascular Diseases Research | 2 | $513,379 |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $229,474 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Defense | 1 | $2.0 million |
| Department of Health and Human Services | 3 | $742,853 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Symclot: synthetic platelet mimetic particles for augmenting hemostasis in patients requiring extracorporeal support | Military Medical Research and Development | September 11, 2023 | $2.0 million |
| Increasing efficiency of sdfv production in a tobacco-based system for synthetic platelet design - project summary uncontrolled bleeding is a significant clinical problem in both civilian and military traumatic injuries; in both cases, exsanguination prior to hospitalization is the primary cause of | Cardiovascular Diseases Research | March 5, 2022 | $258,501 |
| Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma - project summary uncontrolled bleeding is a significant clinical problem in both civilian and military traumatic injuries; in both cases, exsanguination prior to hospitalization is the primary cause of | Cardiovascular Diseases Research | May 21, 2021 | $254,878 |
| Symheal: a novel therapy for treating non-healing diabetic ulcers - project summary non-healing wounds are a significant clinical problem both in the united states and globally. These wounds, defined as wounds that remain unhealed for upwards of 12 weeks, result in diminished quality of life for pat | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 19, 2022 | $229,474 |
Questions people ask
How much federal grant money does Selsym Biotech, Inc. get?
$2.7 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Selsym Biotech, Inc. the most?
The Department of Defense, with $2.0 million in 1 award. The Department of Health and Human Services follow.
What is Selsym Biotech, Inc.'s largest federal grant?
$2.0 million under Military Medical Research and Development, with its first action in the period on September 11, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Selsym Biotech, Inc.?
Its largest are Military Medical Research and Development, Cardiovascular Diseases Research and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Cary
- Wake County Public Schools
- Town of Cary
- Ncasi Foundation
- Focal Medical, Inc.
- Triad Math and Science Academy Company
- Atom Bioworks Inc
- Epipointe LLC
- Gradient Medical Inc.
Largest federal grant recipients in North Carolina · Federal grants in North Carolina